Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cash not forcing Oclassen IPO

Cash not forcing Oclassen IPO

With break-even cash flow from product sales and a full pipeline of later-stage products in the clinic, Oclassen Pharmaceuticals Inc. has seemed especially fitted to the increasingly rigorous demands of

Read the full 356 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers